Effective vaccines inducing lifelong protection against many important infections such as respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), influenza and Epstein-Barr virus (EBV) are not yet available despite decades of research. As an alternative to a protective vaccine we developed a genetic engineering strategy in which CRISPR/Cas9 was utilized to replace endogenously-encoded antibodies with antibodies protective against RSV, HIV, influenza or EBV in primary human or murine B cells. The engineered antibodies were expressed in up to 59% of primary B cells under the control of endogenous regulatory elements, which maintained normal antibody expression and secretion.
Protective vaccines have reduced morbidity and mortality from several infectious diseases in large part by activating the humoral immune response and subsequent production of high affinity pathogen-specific antibodies produced by B cells. Unfortunately, vaccines for many common diseases
are not yet available despite considerable research efforts. One example is RSV, a common pathogen that infects the upper and lower respiratory tracts. RSV is a serious threat to infants, the elderly, those with cardiopulmonary disease, and those undergoing hematopoietic stem cell transplant, where it is a significant cause of morbidity and mortality [1] [2] [3] . The first RSV vaccine trial occurred in 1966 but proved harmful when subsequent natural infection caused severe lower respiratory disease and two deaths 4 .
The second RSV vaccine trial occurred in 2016 and also failed to protect against infection 5 . While several other candidate RSV vaccines are being developed, it is unclear if any will elicit a protective response.
Despite the failure of vaccine trials, evidence exists for antibody-mediated protection against RSV. Several monoclonal antibodies including the RSV-specific monoclonal antibody palivizumab have been shown to protect against RSV infection in vitro or in vivo 6, 7 . Similarly, monoclonal antibodies protective against HIV, influenza, EBV, human metapneumovirus virus, Dengue, Zika, Ebola and many other pathogens are also being developed 8 . However, the infusion of monoclonal antibodies like palivizumab is limited to high risk populations because monthly reinfusion is required to maintain protection. While new approaches to increase the antibody half-life after injection have been developed 9 , even the most promising of these strategies would require lifelong reinfusion to maintain protection.
To overcome the need for reinfusion, alternative strategies to generate long-term immunity have been explored. One approach involves viral transduction of muscle cells with an adenoviral vector encoding a protective antibody 10, 11 . Another approach is transduction of hematopoietic stem cells with a lentivirus-encoded secreted antibody, which are differentiated into antibody-secreting plasma cells in vitro prior to infusion, or allowed to differentiate in vivo after infusion 12, 13 . A shared limitation to both the adenoviral/muscle and lentiviral/stem cell approaches is that the level of antibody produced is fixed and unresponsive to infection. In contrast, protective vaccines elicit both long-lived memory B cells and antibody-secreting plasma cells. Memory B cells express a membrane bound form of antibody that allows these cells rapidly respond and differentiate into additional antibody-secreting cells upon infection.
In an effort to mimic the protective B cell response, we developed a genetic engineering strategy that allowed for the expression of protective antibodies against RSV, HIV, influenza or EBV in mouse or human B cells under endogenous regulatory elements. This was challenging because fully functional B cells require alternative splicing and polyadenylation to produce membrane bound as well as secreted antibody, a process which is difficult to recapitulate in a viral transgene 14, 15 . Adding an additional level of difficulty, antibodies are produced as the product of two genes, heavy chain gene (IgH) and either the kappa (IgL-k) or lambda (IgL-l) light chain gene. Targeting the heavy chain locus was complicated by the large size and extreme genetic heterogeneity of this area in antibodyexpressing B cells. Each developing B cell undergoes recombination of V, D, and J segments over more than a megabase of DNA within the heavy chain locus, and this results in variable regions that are essentially unique to each cell 16 . This sequence variability makes directly targeting antibody coding regions challenging, and replacement of the entire heavy chain locus has been inefficient to date 17 . To bypass this complexity, we developed a single cut approach where the full light chain linked to the heavy chain VDJ was inserted into an intronic region of the heavy chain locus. Using this approach we find that both murine and human B cells can be efficiently engineered and a single transfer of murine B cells engineered to express an RSV-specific antibody can protect a recipient animal from infection for several months.
Results

Targeting strategy and emAb cassette design
To circumvent the complexity of the antibody heavy chain gene, we focused upon a small 2600 nucleotide region of DNA present in all B cells between the last J gene segment and the region involved in class switching. This region was further limited due to the presence of a critical intronic Eμ enhancer, one of several strong enhancer elements that cooperates to drive high level expression of recombined VDJ genes despite the weak core promoters of V gene segments 18, 19 . Activity of these enhancers is regulated in part by the proximity of promoters relative to the Eμ enhancer, and insertion of a transgene between the recombined VDJ segments and the Eμ enhancer can completely block transcription of the upstream VDJ segment 20 . We therefore inserted a synthetic VDJ under the control of a heavy chain promoter upstream of the Eµ enhancer would allow for physiological expression of the inserted engineered monoclonal antibody, which we termed an "emAb".
To enable one-hit insertion we designed an emAb cassette that contained a heavy chain promoter followed by the complete light chain linked to a recombined heavy chain VDJ containing a splice junction to allow for splicing to downstream endogenous heavy chain constant regions ( Fig. 1a ).
Utilizing the endogenous heavy chain constant region reduced the insert size and allowed emAbs to be expressed in membrane-bound and secreted forms of all isotype classes under the control of endogenous regulatory elements. When expressed, the emAb light chain is physically linked to the heavy chain with a 57 amino acid glycine-serine linker ( Fig. 1b ), which has been used previously in single chain Fab fragments 21 . The linker also contained three tandem Streptag-II motifs to facilitate the detection and enrichment of engineered cells 22 . Physically linking the heavy and light chains also minimized the possibility of mispairing between an inserted emAb heavy chain and the endogenous light chain.
CRISPR/Cas9-mediated emAb expression in RAMOS B cells
Insertion and expression of an emAb cassette was first tested in the Burkitt-lymphoma derived RAMOS B cell line that natively expresses membrane-bound and secreted antibodies. Analyzing the region between the terminal J segment and Eµ using the CrispRGold algorithm 23 , several potential Cas9 guide RNA (gRNA) binding sites were identified. We focused upon gRNA huIgH296, which targeted a region was 296 nucleotides downstream of IgHJ6 where no single nucleotide polymorphism (SNP) with a frequency above 1% have been reported 24 . Electroporation of RAMOS cells with huIgH296 gRNA precomplexed with Cas9 protein resulted in efficient DNA cutting, with insertions or deletions (indels) at this site being detected in ~72% of genomic heavy chain DNA ( Fig. 2a ). After electroporation, we incubated cells with AAV encoding an engineered aRSV-emAb cassette derived from palivizumab flanked by 450 nucleotide homology arms on either side of the huIgH296 target site.
Since the AAV does not include the heavy chain constant regions which are essential for antibody expression, RAMOS cells would only gain the ability to bind RSV F antigen if the aRSV-emAb cassette was successfully inserted into the heavy chain locus. Flow cytometry was used to assess aRSV-emAb expression on the cell surface by measuring binding to fluorescent RSV F antigen and streptactin, a modified streptavidin with high affinity for the Streptag-II motifs in the linker 25 . Using this approach, ~30% of aRSV-emAb-engineered RAMOS cells bound RSV F antigen and streptactin compared to less than 0.3% of control RAMOS cells ( Fig. 2b, c) . In order to assess the functionality of the aRSV-emAb, RAMOS cells binding RSV antigen and streptactin were FACS-purified to create a aRSV-emAb + cell line. To confirm functional interaction between RSV-emAb + and the BCR signaling complex, control and aRSV-emAb + RAMOS cells were stimulated with tetramerized RSV F antigen or with polyclonal aIg F(ab')2 antibody. Only RSV-emAb + cells fluxed calcium in response to RSV F antigen, whereas and aRSV-emAb + and control RAMOS cells had similar responses to aIg ( Fig. 2d, e ). These results indicate that emAb engineering reprograms B cells with a functional monoclonal antibody.
CRISPR/Cas9-mediated emAb expression in primary human B cells
We next engineered human primary B cells using a multistep process of expansion and differentiation ( Fig. 3a ). Human B cells were MACS-purified from PBMCs and stimulated with a cocktail of cytokines, a multimerized CD40 ligand and CpG for 48 hours prior to electroporation with huIgH296 gRNA/Cas9. Sequencing of genomic DNA revealed the presence of indels in ~67% of heavy chain DNA sequences from six independent donors ( Fig. 3b ). To test the performance of the emAb backbone across multiple independently derived antibodies, we designed three additional emAb cassettes encoding for the HIV-1 broadly neutralizing antibody VRC01, the influenza broadly neutralizing antibody MEDI8852, and the EBV neutralizing antibody AMM01 [26] [27] [28] . All emAb cassettes were efficiently introduced into primary human B cells and resulted in the generation of populations which bound RSV F antigen, influenza hemagglutinin (HA) stem, EBV gH/gL or HIV-1 Envelope (Env) ( Fig. 3c ). Tests of aRSV-emAb engineering in seven independent donors resulted in RSV antigen being bound by 16-44% of engineered B cells, compared to under 1% of mock engineered control B cells. The emAb expression efficiency ranged from 5-59% for the three additional antiviral emAbs ( Fig. 3d ). All four emAb B cell populations also secreted engineered antibodies when induced to differentiate into antibody-secreting cells through additional culture ( Fig. 3e ). These data demonstrate the flexible nature of the emAb platform for engineering primary B cells to produce and secrete protective monoclonal antibodies.
Engineered B cells can co-express emAbs off of both heavy chain loci
Work with transgenic mice demonstrated that productive VDJ sequences on both heavy chain loci results in simultaneously transcription and translation of both heavy chains 29 . These results indicate that if the emAb cassette was only inserted into the heavy chain locus that did not undergo VDJ recombination or was otherwise recombined in a way that did not produce a productive heavy chain, cells simultaneously expressing their endogenous antibodies and emAbs could be produced (Fig. 4a ).
This would be problematic if the endogenous antibody caused autoimmune tissue destruction due to binding self-antigens. This is a concern given that up to 20% of the naive B cell repertoire has been shown to express antibodies that can bind self-antigens 30 . To determine whether B cells co-expressing both the emAb and endogenous antibodies were produced, we FACS-purified B cells that expressed antibodies utilizing lambda light chains ( Fig. 4b ) prior to engineering with aFlu-emAb, which utilized a kappa light chain. Since many cells in the culture downregulated surface BCR expression as a result of the culture conditions, we gated on cells expressing high levels of CD79b to focus on cells retaining high surface BCR expression ( Fig. 4b ). Within the aFlu-emAb engineered CD79b + B cells, many cells that gained the ability to bind Flu hemagglutinin (HA) stem antigen lost surface expression of the lambda light chain (Fig. 4b ). The loss of lambda light chain expression indicated that the inserted emAb cassette blocked expression of the endogenous antibody in these cells. However, around half of Flu HA stem-binding emAb B cells retained lambda light chain expression on the cell surface ( Fig. 4b, c ).
These results suggested that in around half of the cells, emAb insertion occurred on the non-productive heavy chain locus, resulting in co-expression of the emAb and the endogenous antibody.
The expression of emAb from both the productive and non-productive heavy chain offered the possibility of producing dual-emAb B cells by insertion of a different cassette into each locus. To test this possibility, we assessed B cells engineered simultaneously with AAVs encoding aRSV-emAb and aFlu-emAb cassettes. Simultaneous engineering of cells with aRSV-emAb and aFlu-emAb emAb resulted in ~6% of cells binding both RSV F and Flu-HA stem, a population which is not detected in control B cells, or cells that were engineered with the individual AAVs followed by co-culture ( Fig. 4d ).
Taken together, these results demonstrated that emAbs can be simultaneously expressed by both heavy chain loci.
Murine emAb B cells protect against RSV infection
Having demonstrated the ability to engineer primary B cells, we next assessed the protective capability of these cells in a murine model of infection. Murine emAb-expressing B cells were produced using a process of priming, electroporation and emAb cassette delivery, and expansion similar to that used in human primary B cells ( Fig. 5a ). Electroporation in combination with pre-complexed muIgH367 gRNA and Cas9 resulted in indels in ~80% of target alleles ( Fig. 5b ). Delivery of a murine aRSV-emAb cassette encoded by AAV resulted in 8-24% of murine B cells binding RSV antigen two days later ( Fig.   5c, d ). RSV antigen-binding of 1-7% of B cells could be detected when an aRSV-emAb cassette was delivered during the electroporation as a double stranded DNA (dsDNA) containing short 36 nucleotide homology regions ( Fig. 5c, d) , offering a potential for producing emAb B cells without the use of an AAV.
To assess the protective ability of aRSV-emAb B cells, 1.5 x 10 7 CD45.1 + Balb/cByJ mouse B cells binding RSV antigen were transferred into wild-type CD45.2 + Balb/cByJ mice ( Fig. 6a ). Six days following transfer, 3-9 µg/mL of RSV-specific antibodies were present in the blood of mice that received aRSV-emAb B cells, but not control B cells (Fig. 6b ). Animals were subsequently challenged intranasally with 10 6 PFU of RSV and virus was measured in the lung five days later. Around 5000 PFU of RSV could be detected in lungs from control mice that did not receive cells, and recipients of control B cells (Fig. 6c ). In contrast, RSV was nearly undetectable in mice that received aRSV-emAb B cells ( Fig. 6c ). This protection was comparable to the protection afforded by the injection of a clinical dose, 15 mg/kg, of palivizumab two days before infection.
One of the most susceptible groups for RSV infection are hematopoietic stem cell transplant recipients. Due to the profound immunodeficiency resulting from transplant, RSV infection in the three month period post-transplant carries a significant risk of lower respiratory tract infection, pneumonia, and death 31 . For this reason, we tested the capacity of aRSV-emAb B cells to provide long-term protection in the immunodeficient Rag1 -/mice, which lack B and T cells ( Fig. 6d ). Transfer of 1.5 x 10 7 CD45.1 + C57Bl/6 aRSV-emAb B cells into Rag1 -/mice led to a rapid accumulation of sustained titer of above 40 µg/mL RSV-specific antibodies, which remained at this level for 40 days (Fig. 6e ). Beginning at day 40, titers declined to ~5 µg/mL 72 days after cell transfer ( Fig. 6e ). Despite this decline in titers, intranasal challenge of mice with RSV 82 days after aRSV-emAb B cell transfer revealed near complete protection from infection ( Fig. 6f ). Analysis of transferred CD45.1 + cells after RSV infection revealed thousands of CD38 + memory aRSV-emAb B cells in the spleen, and hundreds of CD138 + aRSV-emAb-secreting cells in the bone marrow ( Fig. 6g , h, Extended Data Fig. 1 ). Together, these results demonstrate that B cells can be efficiently engineered to provide robust and durable protection against infection.
Discussion
The isolation of monoclonal antibodies has transformed medicine as therapeutics [32] [33] [34] . However, the use of antibody-producing primary B cells in adoptive cellular therapy has lagged behind that of other cell types. There has been some recent genetic engineering work focused on taking advantage of the potent protein secretion capabilities of B cells to produce non-antibody therapeutic proteins 35, 36 , but the immense sequence diversity of the antibody repertoire has represented a major barrier to genome engineering of B cell specificity. We bypassed the sequence diversity obstacle by targeting an intronic region, allowing for universal B cell engineering without a priori knowledge of the endogenous VDJ sequences. Insertion of emAb cassettes into this region was complicated by the ability of B cells to simultaneously express productive heavy chains from both alleles, which allowed the emAb to be expressed from one allele and an endogenous heavy chain from the other. Endogenous antibody/emAb co-expression can be circumvented by selecting for pure emAb-expressing B cells by selecting against B cells that express both kappa and lambda light chains when the endogenous antibody and emAb antibodies express one or the other. Alternatively, B cells can be engineered and selected based upon the simultaneous expression of two emAbs. The latter strategy is intriguing since complimentary epitopes on the same pathogen or escape mutations could be simultaneously targeted by the same engineered cells.
Engineered emAb receptors are not limited by the gene segments and recombination events that generate the endogenous B cell repertoire. This could be important in situations where current vaccines have failed. For example, many of the broadly neutralizing antibodies which have been identified for HIV-1 contain features which are rare in the naive B cell repertoire 37 . As an alternative to isolation of rare antibodies, targeting domains could be designed in silico based either on the backbone of antibody variable domains, or entirely novel high affinity binding domains 38, 39 . Combining these approaches with the emAb platform could allow targeting of pathogens for which no protective antibody has been isolated. technology is being developed to bypass patient-specific in vitro preparation of adoptive cellular therapies such as the production of universal donor cells 40 , as well as nanocarrier driven in vivo transduction of primary cells 41 .
In summary, we have demonstrated specific and efficient engineering of primary mouse and human cells to produce multiple potent antiviral antibodies using the emAb platform. Modified heavy chain loci in these engineered B cells retain the ability to undergo alternative splicing to produce both cell surface BCR and secreted antibodies and produced protective levels of antibody following infusion into mice.
This technique offers the possibility of engineering humoral immunity to produce sterilizing immunity to diseases for which no current therapy exists.
Methods
Cell lines
3T3-msCD40L were obtained from Dr. Mark Connors at the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH (Cat#12535) and cultured in DMEM medium with 10% fetal calf serum (Gibco), 100 U/ml penicillin plus 100 μg/mL streptomycin (Gibco), and G418 (350 μg/mL). RAMOS cells were obtained from ATCC (CRL-1596 ™ ) and cultured in RPMI medium with 10% fetal calf serum (Gibco) and 100 U/mL penicillin plus 100 μg/mL streptomycin (Gibco). HEK293 cells were obtained from ATCC (CRL-1573 ™ ) cultured in DMEM medium with 10% fetal calf serum (Gibco), 100 U/mL penicillin plus 100 μg/mL streptomycin (Gibco). Vero cells were obtained from ATCC (CCL-8 ™ ) and cultured in DMEM medium with 10% fetal calf serum (Gibco), 100 U/mL penicillin plus 100 μg/mL streptomycin (Gibco). 
Design of single-chain antibody templates sequences
Production of recombinant emAb-AAV
To generate AAV plasmids for homologous recombination, linearized AAV backbone was isolated from pAAV-GFP (Addgene, Plasmid #32395) by digestion with SnaB (New England Biolabs), and homology arms for mouse and human heavy chain flanking an EcoRV restriction site inserted using NEB builder HiFi DNA assembly master mix (New England Biolabs). EmAb constructs were then synthesized as gene fragments (Integrated DNA Technologies) and cloned into the EcoRV site using Gibson HiFi master mix.
AAVs were generated by triple transfection of AAV emAb plasmid, serotype 6 capsid, and adenoviral helper plasmids into HEK293 cells using polyethylenimine (Polysciences). Eighteen hours after transfection, the media was changed to serum-free DMEM and the cells incubated for 48 hours cells prior to being lysed by freeze-thaw, treated with 20U of benzonase (Thermo Fisher Scientific) per 1 mL of viral lysate for 30 minutes at 37 o C, then purified over iodixanol gradient. Purified AAV was concentrated into 1x DPBS using an Amicon Ultra-15 column (EMD Millipore) 42 prior to viral titer determination by qPCR of AAV genomes 43 , which ranged from 5 × 10 10 to 10 12 per microliter.
Production of murine double stranded DNA emAb templates
dsDNA templates containing short homology regions were generated from aRSV-emAb AAV plasmids through PCR amplification using Platinum PCR Supermix High Fidelity (Thermo Fisher Scientific) and modified DNA oligos. PCR product was purified and concentrated using minElute PCR cleanup columns (Qiagen). The following primers were used for amplification, with mouse genomic homology region in bold and phosphorothioate stabilized DNA bonds denoted by *: 
Assessment of gRNA activity by Sanger sequencing
Total genomic DNA was isolated from 0.5-2 x 10 6 mock and cas9/gRNA treated cells two-five days following electroporation using the DNeasy kit (Qiagen). The genomic DNA region flanking the gRNA target site was amplified by PCR using the following primers:
Mouse IgH Forward, GGCTCCACCAGACCTCTCTA Mouse IgH Reverse, AACCTCAGTCACCGTCTCCT Human IgH Forward, ACAGTAAGCATGCCTCCTAAG Human IgH Reverse, GCCACTCTAGGGCCTTTGTT The resulting PCR product was purified using minElute reaction cleanup kit (Qiagen) and Sanger sequenced (Genewiz). The frequency of indels in Cas9/gRNA electroporated cells relative to mock electroporated cells was determined using the ICE algorithm 44 .
Protein antigens:
Pre-fusion RSV F antigen trimer, EBV gH/gL complex, and a modified HIV Envelope GP140 trimer (426c TM4DV1-3) were produced as described 28, 45, 46 . Stabilized influenza HA stem was produced from VRC clone 3925, derived from strain H1 1999 NC as described 47 . All antigens were conjugated to Biotin NHS ester (Thermo Fisher Scientific) followed by tetramerization with streptavidin-PE, streptavidin-APC or streptavidin (all from Prozyme) as described previously 48 . RSV F antigen was conjugated to Alexa For ex vivo analysis of transferred cells after RSV infection in mice, single cell suspensions of spleen and bone marrow were generated by manual disassociation and filtration. Cells were stained with anti-CD45.1 APC (A20, Biolegend) and purified anti-CD16/32 (2.4G2, BioXcell) for 30 minutes on ice, washed with FACS buffer and then incubated with 25 μL of anti-APC conjugated magnetic microbeads (Miltenyi Biotec). Following a 15 -30 minute incubation on ice, 3 mL of FACS buffer was added and the sample was passed over a magnetized LS column (Miltenyi Biotec). The tube and column were washed once with 5 mL of FACS buffer and then removed from the magnetic field. Five mL of FACS buffer was pushed through the column with a plunger twice to elute column-bound cells. Cells from the column-bound and 1/40 of the column flow through fractions were stained as described above. 20,000
AccuCheck counting beads (Invitrogen) were added to the samples to calculate total cell numbers.
Calcium flux was measured by flow cytometry with the Fluo-4 Direct kit (Thermo Fisher Scientific).
Briefly, 1.5×10 6 cells were labelled with 1 mL Fluo-4 according to manufacturer instructions for 30 minutes at 37 o C. Fluo-4 baseline florescence was measured for 60 seconds, then cells were stimulated with 1 µg tetramerized RSV F antigen, followed by 180 seconds of measurement, and finally cells were simulated with 1 µg ionomycin in DMSO, and florescence was measured for an additional 60 seconds.
Florescence intensity data was binned by time and displayed as fold change over baseline measurement. Flow cytometry data was analyzed using FlowJo X software (Tree Star).
Animals
Animal studies were approved and conducted in accordance with the Fred Hutchinson Cancer Center Institutional Animal Care and Use Committee. Six-to ten-week old male and female BALB/cByJ, BALB/cByJ-CD45.1 congenic, C57bl/6-Rag1-/-(Rag1 -/-), and C57bl/6-CD45.1 congenic mice were obtained from the Jackson Laboratory. For transfer of emAb B cells, age matched BALB/cByJ mice or Rag1 -/mice received a single intraperitoneal (IP) injection of emAb or control B cells derived from CD45.1 + congenic donor mice, or a single IP injection of 15 mg/kg palivizumab at the indicated two days prior to RSV challenge.
RSV infections and titer measurement.
In RSV challenge experiments, mice were inoculated intranasally with 10 6 PFU of sucrose purified RSV expressing eGFP 49 in 40 µL 1xDPBS. Lungs were harvested five days post-infection and the titer was determined using a plaque assay. In brief, lungs were homogenized in 2 mL of DMEM using a GentleMACS M dissociator using preset program lung_02 (Miltenyi Biotec) followed by centrifugation at 400xg for 10 minutes. Supernatant was flash frozen and stored at -80 o C. The supernatant was diluted 1:10 and 1:20 in DMEM and 100 µL of each dilution was added duplicate to confluent Vero cells in 24 well flat-bottoms tissue-culture plates and incubated for 2 hours at 37°C. An overlay of 0.8% methylcellulose was then added and plates incubated for five days prior to imaging on a Typhoon imager (GE Healthcare) with filter settings for eGFP. The titer in pfu/lung was calculated by counting the number of eGFP + plaques with ImageJ software in the highest positive dilution and correcting for the dilution factor. 
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 7. Pairwise statistical comparisons were performed using unpaired two-tailed t-test with Welch's correction. Unless otherwise indicated, values are given as mean and the error bars represent standard deviation. 
